NIH Closes Doors for Secret Grant Review Sessions
Published Date: 5/12/2026
Notice
Summary
The Center for Scientific Review is holding several closed virtual meetings in late May and June 2026 to review important grant applications. These meetings protect private info and trade secrets while deciding which research projects get funding. Scientists and research institutions waiting on grants should note these dates as they impact funding decisions.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 0 costs, 1 mixed.
Grant review dates affect applicants
The Center for Scientific Review will hold closed virtual grant-review meetings on May 29, 2026; June 11, 2026; June 15-16, 2026; and June 16, 2026. If you are a scientist or research institution waiting on NIH grant decisions, these meetings set the dates when your applications will be reviewed and therefore affect the timing of funding decisions.
Confidentiality protections for applicants
The meetings are closed under 5 U.S.C. 552b(c)(4) and (c)(6) to protect confidential trade secrets, commercial property like patentable material, and personal information about individuals linked to grant applications. This protects applicants' proprietary information and personal privacy during the review process.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16683, Proposed Collection; 60-Day Comment Request; Data Use Certification for the NIH National Institute on Drug Abuse Data Share Site
The purpose of this notice is to inform the public of the information collection requirement for the NIDA Data Share, the data use terms and conditions, and to request a progress report statement at the time of renewal. In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-16544, Government-Owned Inventions; Availability for Licensing
The inventions listed below are owned by an agency of the U.S. Government and are available for licensing to achieve expeditious commercialization of results of federally-funded research for the benefit of the public health.
2026-16440, NIH Owned Invention Available for License: Soluble Tissue Factor, a Novel Target, and Antibodies, for Diagnosis, Prevention and Treatment of Thrombosis and Related Conditions
Scientists at the National Cancer Institute (NCI) have discovered a novel therapeutic, diagnostic and prognostic target for thrombosis: Soluble Tissue Factor (sTF). NCI has generated first-in- class antibodies and platform selectively neutralizing pathological coagulation while preserving normal hemostasis. This platform technology can be used to prevent, diagnose and treat pathological thrombosis caused by a variety of clinical conditions-including cancer, sepsis, infectious diseases (e.g., COVID), autoimmune disorders, trauma, heart conditions and inflammatory conditions. It offers a much more sensitive and specific test of thrombosis than the current D-dimer test. It may be applicable to any clinical condition which induces necroptosis, pyroptosis and NETtosis, such as cancer, neurodegenerative disease, ischemia-reperfusion and acute injuries, traumatic injuries, bacterial and viral infections, cardiovascular conditions, and atherosclerosis, inflammatory, autoimmune conditions, and others.
2026-16071, Proposed Collection; 60-Day Comment Request: The Impact of Clinical Research Training and Medical Education at the Clinical Center on Physician Careers in Academia and Clinical Research (Clinical Center)
In compliance with the requirement of the Paperwork Reduction Act of 1995, for opportunity for public comment on proposed data collection projects, the Clinical Center, the National Institutes of Health (NIH) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-15565, Proposed Collection; 60-Day Comment Request, Data Use Certification for the NIH Brain Development Cohorts (NBDC) Data Hub, (National Institute on Drug Abuse)
In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval. The purpose of this revision is to update instructions for the Research Data Use Statement and the Progress Report, and to add new instructions for attesting to National Institute of Standards & Technology (NIST) security compliance, and for a Project Close-out at the time of project completion. Burden levels remain unchanged.
2026-14966, Government-Owned Inventions; Availability for Licensing
The National Institutes of Health is offering a new Ebola vaccine invention for companies to license and develop quickly. This vaccine targets the Bundibugyo virus and promises fast and lasting protection, helping stop outbreaks in Central Africa. Businesses interested in licensing should act soon to bring this life-saving tech to market and can contact NIH for details.
Previous / Next Documents
Previous: 2026-09322, Certain Crystalline Silicon Photovoltaic Products From Taiwan: Preliminary Results of Antidumping Duty Administrative Review; 2024-2025
The U.S. Department of Commerce checked if solar products from Taiwan were being sold too cheaply in the U.S. from Feb 2024 to Jan 2025 and found they were not. This means no extra taxes (antidumping duties) will be added for now. Companies involved, especially EEPV Corp., can share their thoughts before the final decision.
Next: 2026-09324, National Institute of Allergy and Infectious Diseases; Notice of Meetings
The National Institute of Allergy and Infectious Diseases is holding virtual meetings on June 22, 2026, to review grant applications and share important updates. These meetings affect researchers and organizations seeking funding, with some sessions open to the public online and others closed to protect privacy. No new funding amounts are announced, but the grant review could impact future research support.